Table 2. Costs and utilities used in the cost-effectiveness analysis.
| Costs of treatment | Distribution | Source | ||
|---|---|---|---|---|
| Treatment strategy | Costs in euro 2014 | |||
| PegIFN/RBV G1-4 (48 weeks) | 29,712 | Gamma (k = 29,712, θ = 1) | Own cost calculation a | |
| PegIFN/RBV G2-3 (24 weeks) | 19,298 | Gamma (k = 19,298, θ = 1) | Own cost calculation a | |
| DAA/RBV G2-3 (22 weeks) | 106,476 | Gamma (k = 106,476, θ = 1) | Own cost calculation a | |
| Dual DAA therapy b (12 weeks) | 84,216 | Gamma (k = 84,216, θ = 1) | Own cost calculation a | |
| Annual costs per health state before or after treatment | ||||
| Chronic HCV | F0-F2 | 130 | Gamma (k = 130, θ = 1) | AMC/PHSA |
| F3 | 289 | Gamma (k = 289, θ = 1) | AMC/PHSA | |
| F4 | 433 | Gamma (k = 433, θ = 1) | AMC/PHSA | |
| DC | 27,905 | Gamma (k = 27,905, θ = 1) | [49] | |
| HCC | 21,389 | Gamma (k = 21,389, θ = 1) | [49] | |
| After SVR | F0-F2c | 179 | Gamma (k = 179, θ = 1) | AMC/PHSA |
| F3 | 227 | Gamma (k = 227, θ = 1) | AMC/PHSA | |
| F4 | 496 | Gamma (k = 496, θ = 1) | AMC/PHSA | |
| Utilities d,h,i | ||||
| Utility value | ||||
| SVR | F0-F1 | 0.82 | Beta (α = 29.6, β = 12.87) | [47] |
| F2-F3 | 0.72 | Beta (α = 38.19, β = 24.21) | [47] | |
| F4 | 0.62 | Beta (α = 46.77, β = 41.98) | e | |
| Chronic HCV | F0-F1 | 0.77 | Beta (α = 33.90, β = 17.89) | [47] |
| F2-F3 | 0.66 | Beta (α = 43.34, β = 33.91) | [47] | |
| F4 | 0.55 | Beta (α = 52.78, β = 60.12) | [47] | |
| DC | 0.45 | Beta (α = 61.37, β = 99.07) | [47] | |
| HCC | 0.45 | Beta (α = 61.37, β = 99.07) | [47] | |
| Treatment with PegIFN | F0-F1 | 0.66 | Beta (α = 43.34, β = 33.91) | [47] |
| F2-F3 | 0.55 | Beta (α = 52.78, β = 60.12) | [47] | |
| F4 | 0.45 | Beta (α = 61.37, β = 99.07) | e | |
| PegIFN-free treatment | F0-F1 | 0.72 | Beta (α = 38.19, β = 24.21) | f |
| F2-F3 | 0.61 | Beta (α = 47.63, β = 44.23) | f | |
| F4 | 0.50 | Beta (α = 57.08, β = 77.22) | f | |
Abbreviations: AMC: Amsterdam Medical Center; PHSA: Public Health Service of Amsterdam; G: genotype; SVR: sustained virological response
a For more detailed information, see Table B in S1 File.
b Costs of sofosbuvir and daclastavir in the Netherlands as in 2016.
c Healthcare utilization only once after achieving SVR.
d Utilities were multiplied by 0.85 in the analyses to account for drug dependency.
e Similar utility decrement assumed as the decrement from F0-F1 to F2-F3 in the chronic HCV health state.
f During IFN-free treatment, we assumed a lower utility decrement (-0.05 decrement instead of -0.11 decrement during treatment with PegIFN) than the decrement during PegIFN treatment.
h In order to use the utilities by Shepherd et al. we assumed that F0-F1 = mild disease, F2-F3 = moderate disease, and F4 = severe disease based on expert medical opinion.
i parameters from the beta distribution of the utilities based on the utilities accounted for drug dependency (see d)